Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO
GeoVax Labs (Nasdaq: GOVX), a biotechnology company focused on developing immunotherapies and vaccines, has announced an upcoming webinar titled 'Now Is Not the Time to Monkey(pox) Around'. The event, scheduled for August 23, 2024, at 11:00am ET, will feature CEO David Dodd providing a detailed overview of Mpox, including insights on its rapid spread and methods for control, treatment, and prevention.
The webinar, hosted by Tribe Public , offers a complimentary registration for participants who can submit questions in advance or during the event. This presentation aims to address the growing concerns surrounding Mpox and highlight GeoVax Labs' potential role in combating the disease.
GeoVax Labs (Nasdaq: GOVX), un'azienda biotecnologica specializzata nello sviluppo di immunoterapie e vaccini, ha annunciato un prossimo webinar intitolato 'Non è il momento di scherzare con Monkey(pox)'. L'evento, programmato per il 23 agosto 2024 alle 11:00 ET, vedrà il CEO David Dodd fornire una panoramica dettagliata di Mpox, inclusi approfondimenti sulla sua rapida diffusione e sulle metodologie di controllo, trattamento e prevenzione.
Il webinar, ospitato da Tribe Public, offre una registrazione gratuita per i partecipanti che possono inviare domande in anticipo o durante l'evento. Questa presentazione mira a trattare le crescenti preoccupazioni relative a Mpox e a mettere in evidenza il ruolo potenziale di GeoVax Labs nella lotta contro la malattia.
GeoVax Labs (Nasdaq: GOVX), una empresa biotecnológica centrada en el desarrollo de inmunoterapias y vacunas, ha anunciado un próximo seminario web titulado 'No es el momento de jugar con Monkey(pox)'. El evento, programado para el 23 de agosto de 2024 a las 11:00 am ET, contará con la participación del CEO David Dodd, quien ofrecerá una visión detallada de Mpox, incluyendo información sobre su rápida propagación y métodos para el control, tratamiento y prevención.
El seminario web, organizado por Tribe Public, ofrece registro gratuito para los participantes que pueden enviar preguntas con anticipación o durante el evento. Esta presentación tiene como objetivo abordar las crecientes preocupaciones en torno a Mpox y resaltar el papel potencial de GeoVax Labs en la lucha contra la enfermedad.
GeoVax Labs (Nasdaq: GOVX)는 면역 요법 및 백신 개발에 중점을 둔 생명공학 회사이며 '원숭이(pox)와 놀 때가 아니다'라는 제목의 웹 세미나를 발표했습니다. 2024년 8월 23일 오전 11:00 ET에 예정된 이 행사에서는 CEO David Dodd가 Mpox에 대한 자세한 개요를 제공하며, 그 빠른 확산과 통제, 치료 및 예방 방법에 대한 통찰력을 포함할 것입니다.
Tribe Public이 주최하는 이 웹 세미나는 참가자들이 사전 또는 행사 중에 질문을 제출할 수 있는 무료 등록을 제공합니다. 이 프레젠테이션은 Mpox와 관련된 증가하는 우려를 다루고 GeoVax Labs가 이 질병 퇴치에 기여할 수 있는 잠재적인 역할을 강조하는 것을 목표로 합니다.
GeoVax Labs (Nasdaq: GOVX), une entreprise biotechnologique axée sur le développement d'immunothérapies et de vaccins, a annoncé un prochain webinaire intitulé 'Ce n'est pas le moment de plaisanter avec Monkey(pox)'. L'événement, prévu pour le 23 août 2024 à 11h00 ET, mettra en vedette le PDG David Dodd qui présentera un aperçu détaillé de Mpox, y compris des informations sur sa propagation rapide et des méthodes de contrôle, de traitement et de prévention.
Le webinaire, animé par Tribe Public, propose une inscription gratuite pour les participants qui peuvent soumettre des questions à l'avance ou pendant l'événement. Cette présentation vise à aborder les préoccupations croissantes concernant Mpox et à mettre en lumière le rôle potentiel de GeoVax Labs dans la lutte contre la maladie.
GeoVax Labs (Nasdaq: GOVX), ein biotechnologisches Unternehmen, das sich auf die Entwicklung von Immuntherapien und Impfstoffen konzentriert, hat ein bevorstehendes Webinar mit dem Titel 'Jetzt ist nicht die Zeit, sich mit Monkey(pox) zu beschäftigen' angekündigt. Die Veranstaltung, die für den 23. August 2024 um 11:00 Uhr ET geplant ist, wird von CEO David Dodd geleitet, der einen detaillierten Überblick über Mpox geben wird, einschließlich Einblicke in seine schnelle Verbreitung und Methoden zur Kontrolle, Behandlung und Prävention.
Das Webinar, das von Tribe Public ausgerichtet wird, bietet eine kostenlose Registrierung für Teilnehmer, die Fragen im Voraus oder während der Veranstaltung einreichen können. Diese Präsentation zielt darauf ab, die wachsenden Bedenken bezüglich Mpox zu erörtern und die potenzielle Rolle von GeoVax Labs im Kampf gegen die Krankheit hervorzuheben.
- Increased visibility and investor engagement through participation in a public webinar
- Opportunity to showcase expertise in Mpox, potentially positioning the company as a leader in this area
- Potential to attract investor interest by addressing a timely and relevant health concern
- None.
Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention
ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc. (Nasdaq: GOVX) ("GeoVax Labs" or the "Company"), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, CEO of GeoVax Labs, will present at Tribe Public’s Webinar Presentation and Q&A Event titled "Now Is Not the Time to Monkey(pox) Around." The Event is scheduled to begin at 8:00am PT / 11:00am ET on Friday, August 23, 2024. To register to join the complimentary event, please visit the Tribe Public LLC website at MonkeyPox.TribePublic.com.
Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at research@tribepublic.com or share their questions via the ZOOM chat feature during the event. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
About Tribe Public LLC
Tribe Public LLC is a San Francisco, CA based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe’s complimentary events focus on issues that the Tribe members care about with an emphasis on hosting management teams from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress and plans. Tribe members primarily include Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers they care about and want to learn from at the Tribe Public website via the Tribe’s FREE “Wish List” process. Visit Tribe Public’s Website to learn more: https://tribepublic.com/
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 | ||
FAQ
When is GeoVax Labs (GOVX) presenting its webinar on Mpox?
What is the title of GeoVax Labs' (GOVX) upcoming webinar on Mpox?
Who will be presenting at GeoVax Labs' (GOVX) Mpox webinar?
How can investors register for GeoVax Labs' (GOVX) Mpox webinar?
